Date: 2014-06-26
Type of information: Nomination
Compound: corporate advisor
Company: Nuevolution (Denmark)
Therapeutic area: Technology - Services
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 26, 2014, Nuevolution announced that Dr. Peter Hirth has joined Nuevolution as a Corporate Advisor. Peter brings 30 years of experience in biotechnology and pharmaceutical discovery to Nuevolution, explicitly from his tremendous successes with companies like Sugen and Plexxikon. At Sugen, Peter grew the company from its inception, and he led the company in its successful clinical development of several kinase inhibitors within oncology. Sugen was acquired by Pharmacia in 1999 and Peter served as President until 2000. Platform based biotech Plexxikon, which was co-founded by Peter in 2000, gained its successes through the pioneering work within fragment based drug discovery, which resulted in the development of several NCEs in a variety of indications. Most know in Plexxikon’s portfolio was the successful development and launch of Zelboraf™ for the treatment of patients with BRAFV600E mutation-positive inoperable or metastatic melanoma. Plexxikon was acquired by Daiichi Sankyo in 2011.
- Furthermore and prior to Sugen, Peter was Vice President at Boehringer Mannheim, and before that, he was a research scientist at the Max Planck Institute, following the completion of his post-doctoral work at the University of California, San Diego. Peter received his Ph.D. in molecular genetics from Heidelberg University, Germany.
Financial terms:
Latest news:
Is general: Yes
